Targeting the Akt-pathway to improve radiosensitivity in glioblastoma

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 951-957

  Narayan, Ravi S ^a   Fedrigo, Carlos Alexandre ^b   Stalpers, Lukas J A ^c   Baumert, Brigitta G ^d   Sminia, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MAASTRO CLINIC   (Netherlands)

Author keywords

DNA damage repair; Glioblastoma multiforme; PI3K Akt pathway; Radiotherapy; Targeted therapy

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFURESERTIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEMCITABINE; GSK 2141795; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NELFINAVIR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RX 0201; SERINE; TEMOZOLOMIDE; TEMSIROLIMUS; THREONINE; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER GENETICS; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA END JOINING REPAIR; DNA METHYLATION; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84876736382     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547286     Document Type: Review

References (84)

1. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes development 2007; 21(21): 2683-710.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta neuropathologica 2007; 114(2): 97-109.
3. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta neuropathologica 2007; 114(5): 443-58.
4. Wen PY, Kesari S. Malignant gliomas in adults. New Eng J Med 2008; 359(5): 492-507.
5. Chen Y, Swanson RA. Astrocytes and brain injury. Journal of cerebral blood flow and metabolism: official J International Society of Cerebral Blood Flow and Metabolism 2003; 23(2): 137-49.
6. Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S. Survival of European patients with central nervous system tumors. Int J cancer. J Int du cancer 2012; 131(1): 173-85.
7. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J neuro-oncology 2012; 107(2): 359-64.
8. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Critical Rev oncology/hematol 2008; 67(2): 139-52.
9. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurologic clinics 2007; 25(4): 1111-39, x.
10. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J radiation oncol, biol, phy 1979; 5(10): 1725-31.
11. Arjona D, Rey JA, Taylor SM. Early genetic changes involved in low-grade astrocytic tumor development. Curr Mol Med 2006; 6(6): 645-50.
12. Grzmil M, Hemmings BA. Deregulated signalling networks in human brain tumors. Biochimica et biophysica acta 2010; 1804(3): 476-83.
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med 2005; 352(10): 987-96.
14. See S-J, Gilbert MR. Chemotherapy in adults with gliomas. Annals Academy Med Singapore 2007; 36(5): 364-6.
15. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical cancer research: an official J Amn Association Cancer Res 2004; 10(6): 1871-4.
16. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Eng J Med 2005; 352(10): 997-1003.
17. Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel Therapies in Glioblastoma. Neurol Res Int 2012; 2012: 1-14.
18. Cancer T, Atlas G. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216): 1061-8.
19. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129(7): 1261-74.
20. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell cycle (Georgetown, Tex.) 2009; 8(16): 2502-8.
21. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Society transactions 2006; 34(Pt 5): 647-62.
22. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15(23): 6541-51.
23. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, N.Y.) 2005; 307(5712): 1098-101.
24. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J cellular mole med 9(1): 59-71.
25. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol cell 2008; 30(2): 203-13.
26. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Frontiers in bioscience: j virtual library 2005; 10: 975-87.
27. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61(10): 3986-97.
28. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273(22): 13375-8.
29. Sun H, Lesche R, Li D-M, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Nat Acad Sci 1999; 96(11): 6199-204.
30. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clinical Investigation 2003; 112(8): 1223-33.
31. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes development 2001; 15(11): 1311-33.
32. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J radiation oncol, biol, phy 2004; 58(3): 927-31.
33. Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Exp Rev Anticancer Therapy 2007; 7(12 Suppl): S45-50.
34. Ramnarain DB, Park S, Lee DY, et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006; 66(2): 867-74.
35. Fan Q-W, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Topics Microbiol Immunol 2010; 347(grade IV): 279-96.
36. Li B, Yuan M, Kim I-A, Chang C-M, Bernhard EJ, Shu H-KG. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004; 23(26): 4594-602.
37. Bleeker FE, Lamba S, Zanon C, et al. Absence of AKT1 mutations in glioblastoma. PloS one 2009; 4(5): e5638.
38. Begg AC, Stewart F a, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11(4): 239-53.
39. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S. The Dual PI3K/mTOR Inhibitor NVPBEZ235 Is a Potent Inhibitor of ATM-and DNA-PKCs-Mediated DNA Damage Responses. Neoplasia (New York, N.Y.) 2012; 14(1): 34-43.
40. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136(5): 823-37.
41. O'Driscoll M, Jeggo P a. The role of double-strand break repair-insights from human genetics. Nat rev Genetics 2006; 7(1): 45-54.
42. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (New York, N.Y.) 2007; 316(5828): 1160-6.
43. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell cycle (Georgetown, Tex.) 2011; 10(13): 2218-32.
44. Toulany M, Lee K-J, Fattah KR, et al. Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs-Dependent DNA Double-Strand Break Repair. Mol cancer res: MCR 2012 Jun 26;
45. Viniegra JG, Martínez N, Modirassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol chem 2005; 280(6): 4029-36.
46. Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol chem 2008; 283(1): 1-5.
47. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol chem 2004; 279(39): 41189-96.
48. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol therapy 2009; 8(8): 730-8.
49. Kao GD, Jiang Z, Fernandes AM, Gupta AK, Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol chem 2007; 282(29): 21206-12.
50. Toulany M, Kehlbach R, Florczak U, et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol cancer therapeut 2008; 7(7): 1772-81.
51. Kim IA, Bae SS, Fernandes A, et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005; 65(17): 7902-10.
52. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Exp opinion Investigational drugs 2010; 19(11): 1355-66.
53. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol cancer therapeut 2003; 2(11): 1093-103.
54. de la Peña L, Burgan WE, Carter DJ, et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol cancer therapeut 2006; 5(6): 1504-10.
55. Becher OJ, Hambardzumyan D, Walker TR, et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 2010; 70(6): 2548-57.
56. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65(18): 8256-65.
57. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical cancer research: an official J Am Association Cancer Res 2007; 13(17): 5183-94.
58. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the un folded protein response. Neoplasia (New York, N.Y.) 2007; 9(4): 271-8.
59. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007; 67(9): 4467-73.
60. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005; 65(11): 4861-9.
61. Li H-F, Kim J-S, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiation oncology (London, England) 2009; 4: 43.
62. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol cancer Therapeut 2010; 9(7): 1956-67.
63. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J clinical oncology: official J Am Soc Clinical Oncol 2011; 29(35): 4688-95.
64. Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J radiation oncology, biology, physics 2011; 80(2): 347-53.
65. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J clinical oncology: official J Am Society Clinical Oncol 2009; 27(4): 579-84.
66. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J National Cancer Institute 2005; 97(12): 880-7.
67. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Eng J Med 2005; 353(19): 2012-24.
68. Kubota N, Okada S, Inada T, Ohnishi K, Ohnishi T. Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation. Cancer letters 2000; 161(2): 141-7.
69. Nakamura JL, Karlsson A, Arvold ND, et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J neuro-oncology 2005; 71(3): 215-22.
70. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica et biophysica acta 2008; 1784(1): 159-85.
71. Koul D, Fu J, Shen R, et al. Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells. Clinical cancer research: an official J Am Association Cancer Res 2011 Dec 16;
72. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell 2007; 12(1): 9-22.
73. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500-8.
74. O'Reilly T, McSheehy PM. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. Translational oncology 2010; 3(2): 65-79.
75. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-56.
76. Maira S-M, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol cancer Therapeut 2008; 7(7): 1851-63.
77. Liu T-J, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol cancer Therapeut 2009; 8(8): 2204-10.
78. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-oncology 2011; 13(4): 384-92.
79. Pitter KL, Galbán CJ, Galbán S, et al. Perifosine and CCI 779 cooperate to induce cell death and decrease proliferation in PTENintact and PTEN-deficient PDGF-driven murine glioblastoma. PloS one 2011; 6(1): e14545.
80. Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol cancer Therapeut 2012; 11(1): 154-64.
81. Xu C-X, Li Y, Yue P, et al. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against nonsmall cell lung cancer in vitro and in vivo. PloS one 2011; 6(6): e20899.
82. Ren H, Chen M, Yue P, et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer letters 2012; (July).
83. Yang S, Xiao X, Meng X, Leslie KK. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PloS one 2011; 6(10): e26343.
84. Williams TM, Flecha AR, Keller P, et al. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol cancer Therapeut 2012; 11(5): 1193-202.